We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

6 hedge funds and large institutions have $859K invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

57% more capital invested

Capital invested by funds: $547K → $859K (+$312K)

9.29% more ownership

Funds ownership: 15.13% → 24.42% (+9.3%)

0% more funds holding

Funds holding: 6 → 6 (0)

90% less call options, than puts

Call options by funds: $2K | Put options by funds: $21K

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
1
Closed
–
Calls
$2K
Puts
$21K
Net Calls
-$19K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IMC Chicago
IMC Chicago
Illinois
+$180K
2
TRCT
Tower Research Capital (TRC)
New York
+$141K
3
Citadel Advisors
Citadel Advisors
Florida
+$11K
4
Morgan Stanley
Morgan Stanley
New York
+$35

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.59K

BIS Hedge Fund Activity: Q1 2024 in Review

6 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2024, worth a combined $859K — up 57% from $547K a quarter earlier.

Fund positioning in BIS was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was IMC Chicago, adding an estimated $180K. The largest seller was UBS Group, cutting an estimated $4.59K.

  • 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $859K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2024, up 57% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2024 and 0 closed out.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2024 was IMC Chicago, an estimated $180K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2024 was UBS Group, an estimated $4.59K sold.

Based on aggregated 13F filings for Q1 2024.